Form 8-K BIO-PATH HOLDINGS, INC. For: Apr 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Roth/MKM Out Positive on Bio-Path Holdings (BPTH), PT $40
April 18, 2024 9:53 AM EDTRoth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).
The analyst comments "BPTH safely completed treatment of dose cohort 2 in its Phase 1/1b trial evaluating BP1002 in rel/ref AML. As expected, dose... More
